U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H48N6O5S2
Molecular Weight 720.9478
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RITONAVIR

SMILES

CC(C)[C@@]([H])(C(=N[C@@]([H])(Cc1ccccc1)C[C@@]([H])([C@]([H])(Cc2ccccc2)N=C(O)OCc3cncs3)O)O)N=C(N(C)Cc4csc(C(C)C)n4)O

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula C37H48N6O5S2
Molecular Weight 720.9478
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in guinea pig and rats. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.20000000000000018 µM [IC50]
0.140000000000000013 µM [IC50]
0.0100000000000000002 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NORVIR

Approved Use

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14)

Launch Date

825638400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.2 μg/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
129 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years
Health Status: healthy
Age Group: 29 years
Sex: M+F
Sources:
Disc. AE: Death fetal...
AEs leading to
discontinuation/dose reduction:
Death fetal (1 patient)
Sources:
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
healthy, 29 years
Health Status: healthy
Age Group: 29 years
Sex: M+F
Sources:
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (grade 2, 1 patient)
Sources:
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Gastrointestinal disorder NOS, Lipids abnormal...
Other AEs:
Gastrointestinal disorder NOS
Lipids abnormal
Insulin resistance
Lipoatrophy
Sources:
AEs

AEs

AESignificanceDosePopulation
Death fetal 1 patient
Disc. AE
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years
Health Status: healthy
Age Group: 29 years
Sex: M+F
Sources:
Hypertension grade 2, 1 patient
Disc. AE
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
healthy, 29 years
Health Status: healthy
Age Group: 29 years
Sex: M+F
Sources:
Gastrointestinal disorder NOS
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Insulin resistance
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Lipids abnormal
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Lipoatrophy
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
yes [IC50 17.3 uM]
yes (co-administration study)
Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing.
Page: 2
yes [IC50 23.5 uM]
yes [IC50 6.2 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Saquinavir soft gelatin capsule: a comparative safety review.
2001
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.
2001
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.
2001 Apr
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
2001 Apr
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
2001 Apr 1
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
2001 Apr 13
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
2001 Apr 15
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.
2001 Apr 15
[An option even for patients with multiple pretreatment].
2001 Apr 2
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].
2001 Apr 2
Antiviral drugs: current state of the art.
2001 Aug
Pharmacology and clinical experience with saquinavir.
2001 Feb
Use of HIV protease inhibitors as pharmacoenhancers.
2001 Feb
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.
2001 Feb
[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].
2001 Feb
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.
2001 Feb
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
2001 Feb
Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.
2001 Feb 10
Ritonavir-induced carbamazepine toxicity.
2001 Jan
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
2001 Jan 20
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
2001 Jan 26
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
2001 Jan 26
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
2001 Jan 5
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.
2001 Jan-Feb
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
2001 Jun
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.
2001 Jun 1
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
2001 Jun 1
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
2001 Jun 1
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
2001 Jun 15
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
2001 Jun 15
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
2001 Jun 15
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.
2001 Mar
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
2001 Mar
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
2001 Mar 1
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
2001 Mar 1
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.
2001 Mar 26
[HIV: a guide on management of seropositive patients].
2001 Mar 3
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
2001 Mar 30
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
2001 Mar 9
Lopinavir/ritonavir.
2001 Mar-Apr
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
2001 May
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.
2001 May
A potential role for interleukin-7 in T-cell homeostasis.
2001 May 15
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
2001 May 25
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
2001 May 25
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
2001 May 25
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
2001 May 4
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
2001 May 5
Patents

Sample Use Guides

600 mg twice-day with meals.
Route of Administration: Oral
Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:55 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:55 UTC 2021
Record UNII
O3J8G9O825
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RITONAVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
NORVIR
Brand Name English
RITONAVIR [VANDF]
Common Name English
RITONAVIR [MI]
Common Name English
RITONAVIR [WHO-DD]
Common Name English
VIRITON
Brand Name English
EMPETUS
Brand Name English
RITONAVIR [INN]
Common Name English
RITONAVIR [USP]
Common Name English
ABBOTT-84538
Code English
VIEKIRAX COMPONENT RITONAVIR
Brand Name English
RITOVIR
Brand Name English
KALETRA COMPONENT RITONAVIR
Common Name English
RITONAVIR [HSDB]
Common Name English
RITONAVIR [USP-RS]
Common Name English
NSC-693184
Code English
ABT-538
Code English
RITONAVIR COMPONENT OF VIEKIRAX
Brand Name English
RTV
Common Name English
RITONAVIR [EMA EPAR]
Common Name English
RITONAVIR [JAN]
Common Name English
RITONAVIR COMPONENT OF KALETRA
Common Name English
RITONAVIR [ORANGE BOOK]
Common Name English
RITONAVIRUM [WHO-IP LATIN]
Common Name English
A-84538
Code English
RITOMUNE
Brand Name English
RITONAVIR RELATED COMPOUNDS MIXTURE
USP-RS  
Common Name English
2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-
Systematic Name English
RITONAVIR [MART.]
Common Name English
2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-
Common Name English
RITONAVIR [USP MONOGRAPH]
Common Name English
RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]
Common Name English
RITONAVIR [WHO-IP]
Common Name English
VIEKIRAX
Brand Name English
5-THIAZOLYLMETHYL ((.ALPHA.S)-.ALPHA.-((1S,3S)-1-HYDROXY-3-((2S)-2-(3-((2-ISOPROPYL-4-THIAZOLYL)METHYL)-3-METHYLUREIDO)-3-METHYLBUTYRAMIDO)-4-PHENYLBUTYL)PHENETHYL)CARBAMATE
Common Name English
RITONAVIR [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX 853
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AR10
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AE03
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-VATC QJ05AE03
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
FDA ORPHAN DRUG 549816
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-VATC QJ05AR10
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AP52
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
EMA ASSESSMENT REPORTS LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AX66
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
NCI_THESAURUS C97366
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
EMA ASSESSMENT REPORTS KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LPV/R)
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AR23
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AP53
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
NDF-RT N0000191001
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
FDA ORPHAN DRUG 509215
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
NDF-RT N0000175889
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
FDA ORPHAN DRUG 484715
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
NDF-RT N0000000246
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
WHO-ATC J05AX67
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
EMA ASSESSMENT REPORTS NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
RITONAVIR
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance.
FDA UNII
O3J8G9O825
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL163
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
INN
7449
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
EVMPD
SUB10342MIG
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
WIKIPEDIA
RITONAVIR
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
RXCUI
85762
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000182137
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
NDF-RT
N0000187064
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
DRUG BANK
DB00503
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
MESH
D019438
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
LACTMED
Ritonavir
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
NDF-RT
N0000185607
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
DRUG CENTRAL
2391
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
NDF-RT
N0000190113
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
NDF-RT
N0000185507
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
EPA CompTox
155213-67-5
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
NDF-RT
N0000190117
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY UDP Glucuronosyltransferases Inducers [MoA]
NDF-RT
N0000190118
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 3A Inducers [MoA]
USP_CATALOG
1604814
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M9636
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1604803
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY USP-RS
NDF-RT
N0000190114
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
PUBCHEM
392622
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
HSDB
7160
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
IUPHAR
8804
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
NCI_THESAURUS
C1609
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
CAS
155213-67-5
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INHIBITOR
POTENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INDUCER
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> INHIBITOR
POTENT
METABOLIC ENZYME -> INHIBITOR
POTENT
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE INACTIVE -> PARENT
MINOR
FECAL
METABOLITE ACTIVE -> PARENT
37.3% in feces 30.4% in urine
MAJOR
FECAL; URINE
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol- 0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC